Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624001150538
Ethics application status
Approved
Date submitted
16/01/2024
Date registered
23/09/2024
Date last updated
23/09/2024
Date data sharing statement initially provided
23/09/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
Creatine and Exercise as a Novel Treatment Strategy for Depression in Adults Aged 18-39 Years
Query!
Scientific title
Creatine and Exercise as a Novel Treatment Strategy for Depression in Adults Aged 18-39 Years
Query!
Secondary ID [1]
311307
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Depression
332555
0
Query!
Condition category
Condition code
Mental Health
329246
329246
0
0
Query!
Depression
Query!
Physical Medicine / Rehabilitation
331593
331593
0
0
Query!
Other physical medicine / rehabilitation
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
There are two separate treatment arms:
Treatment Arm One: 10g Creatine per day for 6 weeks; oral (diluted in flavored cordial in an opaque bottle) without resistance training
Treatment Arm Two: 10g Creatine per day for 6 weeks; oral (diluted in flavored cordial in an opaque bottle) with resistance training as detailed below.
6 weeks resistance training, 3 times per week with at least 48 hours recovery; Whole-Body program
All exercise sessions will be supervised by selected research investigators that are first aid-trained and have previously completed their Certificate 3 and 4 in Fitness
Sessions will be one-on-one at the Swinburne University gym
Exercise intensities will range from 50-80% of a pre-determined maximum strength test and will be performed at an intensity level aiming for 7-9 out of 10 on a Borg Scale
Participants will complete three sessions per week for six weeks; each session will last between 35-45 minutes including a warm-up and warm-down.
Adherence will be monitored by counting the number of sessions completed during the six period and compared to the target of 18 sessions throughout the entire intervention.
Query!
Intervention code [1]
327752
0
Treatment: Other
Query!
Comparator / control treatment
The control/comparator group will undertake 6 weeks resistance training (3 times per week with at least 48 hours recovery; Whole-Body program; exactly the same program as detailed above) as well as receive 10g Maltodextrin per day for 6 weeks (oral; diluted in flavored cordial in an opaque bottle).
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
337101
0
Depression
Query!
Assessment method [1]
337101
0
Participant responses to the following questionnaire: Patient Health Questionnaire-9 (PHQ-9)
Query!
Timepoint [1]
337101
0
Pre-intervention (0 weeks); Post-intervention (6 weeks post intervention commencement)
Query!
Primary outcome [2]
339332
0
Depression
Query!
Assessment method [2]
339332
0
Participant responses to the following questionnaires: Montgomery-Asberg Depression Rating Scale (MADRS) and Depression Anxiety and Stress Scale 21 (DASS-21).
Query!
Timepoint [2]
339332
0
Pre-intervention (0 weeks); Post-intervention (6 weeks post intervention commencement)
Query!
Secondary outcome [1]
430717
0
Muscle Strength
Query!
Assessment method [1]
430717
0
Composite measures of 1-Repetition Maximum Strength for the Bench Press (Upper Body including Pec Major, Shoulders and arms) and Leg Press (Lower Body including hip flexors, quads, gluteals and hamstrings)
Query!
Timepoint [1]
430717
0
Pre-intervention (0 weeks); Post-intervention (6 weeks post intervention commencement)
Query!
Secondary outcome [2]
430718
0
Circulating levels of Brain Derived Neutrophic Factor (BDNF)
Query!
Assessment method [2]
430718
0
ELISA
Query!
Timepoint [2]
430718
0
Pre-intervention (0 weeks); Post-intervention (6 weeks post intervention commencement)
Query!
Eligibility
Key inclusion criteria
- Aged 18-39 years.
- Mild-moderate depression severity (scoring between 5-19 on the Patient Health Questionnaire-9, PHQ-9)
- Body mass index (BMI) is between 18.5-29.9 kg/m².
- Sedentary (less than 150 min/week exercise/ physical activity)
- Not involved in a structured exercise program involving more than 2 exercise sessions per week in the last 6 months
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
39
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Hazardous alcohol or tobacco use using the AUDIT Alcohol Screening Tool
- No current or previous use of creatine supplements
- Physically active (greater than 150 min/week exercise/ physical activity)
- Serious somatic disorder based on a previous diagnosis from a Medical Doctor
- Psychiatric treatment
- Moderately severe and severe depression (PHQ-9>14 or >20 respectively).
- Body mass index (BMI) above 29.9 kg/m²
- Asthma
- Any current or history of respiratory or cardiac conditions
- Diabetes
- Pre-existing renal disease or proteinuria on baseline urinalysis testing
- History of creatinine hypersensitivity
- Concomitant treatment with antiepileptic or antipsychotic medications
- Neurological or psychiatric disorder
- Clinically significant suicidal or homicidal risk
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Permuted block randomisation
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people administering the treatment/s
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
7/10/2024
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
18/08/2025
Query!
Actual
Query!
Date of last data collection
Anticipated
31/10/2025
Query!
Actual
Query!
Sample size
Target
36
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Funding & Sponsors
Funding source category [1]
315560
0
Charities/Societies/Foundations
Query!
Name [1]
315560
0
Barber Dicker Sciences Brain Sciences Foundation
Query!
Address [1]
315560
0
Swinburne University; John Street, Hawthorn, 3122
Query!
Country [1]
315560
0
Australia
Query!
Primary sponsor type
University
Query!
Name
Swinburne University
Query!
Address
John Street, Hawthorn, 3122
Query!
Country
Australia
Query!
Secondary sponsor category [1]
317679
0
None
Query!
Name [1]
317679
0
Query!
Address [1]
317679
0
Query!
Country [1]
317679
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
314459
0
Swinburne Human Research Ethics Committee
Query!
Ethics committee address [1]
314459
0
Swinburne University; John Street; Hawthorn; 3122; Victoria
Query!
Ethics committee country [1]
314459
0
Australia
Query!
Date submitted for ethics approval [1]
314459
0
30/01/2024
Query!
Approval date [1]
314459
0
25/07/2024
Query!
Ethics approval number [1]
314459
0
Query!
Ethics committee name [2]
316092
0
Swinburne University of Technology Human Research Ethics Committee
Query!
Ethics committee address [2]
316092
0
https://www.swinburne.edu.au/research/ethics/human-research/
Query!
Ethics committee country [2]
316092
0
Australia
Query!
Date submitted for ethics approval [2]
316092
0
30/01/2024
Query!
Approval date [2]
316092
0
25/07/2024
Query!
Ethics approval number [2]
316092
0
Query!
Summary
Brief summary
Creatine plays a crucial role in rapidly providing energy to the brain during times of increased demand such as sleep deprivation and mental health conditions (i.e.: depression). Such energy provision is crucial considering the brain is a highly metabolically active organ and requires a constant energy supply. However, current research has only investigated the potential anti-depressant effects of creatine supplementation with traditional pharmacological interventions that are known to induce multiple health side effects and are associated with low success. Considering exercise is a well-established, efficacious treatment option for reducing depressive symptoms for individuals with depression, this proposal will test the hypothesis that the synergistic effects of creatine supplementation and exercise can reuce symptoms of depression and anxiety, while concomitantly improving motivation in adults aged between 18-39 years with mild-to-moderate depression over a six-week period.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
131658
0
Dr Donny Camera
Query!
Address
131658
0
Swinburne University; Department of Health and Biostatistics; Room SPW224 Mail H21 PO Box 218 Hawthorn Vic, 3122
Query!
Country
131658
0
Australia
Query!
Phone
131658
0
+61 403166127
Query!
Fax
131658
0
Query!
Email
131658
0
[email protected]
Query!
Contact person for public queries
Name
131659
0
Donny Camera
Query!
Address
131659
0
Swinburne University; Department of Health and Biostatistics; Room SPW224 Mail H21 PO Box 218 Hawthorn Vic, 3122
Query!
Country
131659
0
Australia
Query!
Phone
131659
0
+61 403166127
Query!
Fax
131659
0
Query!
Email
131659
0
[email protected]
Query!
Contact person for scientific queries
Name
131660
0
Donny Camera
Query!
Address
131660
0
Swinburne University; Department of Health and Biostatistics; Room SPW224 Mail H21 PO Box 218 Hawthorn Vic, 3122
Query!
Country
131660
0
Australia
Query!
Phone
131660
0
+61 403166127
Query!
Fax
131660
0
Query!
Email
131660
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF